UW-Madison Moves Forward with COVID-19 Vaccine (AZD1222) Clinical Trial After Several Week Pause

UW-Madison Moves Forward with COVID-19 Vaccine (AZD1222) Clinical Trial After Several Week Pause

Although TrialSite reported yesterday that both the AstraZeneca and the Johnson & Johnson vaccine trials received the U.S. Food and Drug Administration (FDA) greenlight to resume, the AstraZeneca study had been in delay for several weeks in America. Recently, a University of Wisconsin-Madison principal investigator wanted it on the record that such pauses should be considered a good thing, not a negative. The fact that there is a pause in the study indicates that the FDA regulated system is healthy and functioning well, suggests the study’s principal investigator for UW-Madison, Dr. William Hartman.

Confidence at UW

After a nearly seven week pause, the AstraZeneca COVID-19 vaccine trial at UW, and other sites, is up and running again. Dr. Hartman shared that such pauses shouldn’t prompt worry but rather the opposite, greater confidence and trust in the process. Speaking to local Madison news, Dr. Hartman declared, “We have to realize that pauses like this are very common in trials.” He continued that, “The trials just aren’t under such media scrutiny.”

Driving Forward

According to WKOW, prior to the study’s pause, up to 10,000 people were interested in participatin...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee